Spyre Therapeutics (SYRE) Long-Term Deferred Tax (2022)

Spyre Therapeutics (SYRE) reported Long-Term Deferred Tax of $566000.0 for Q4 2022.

Spyre Therapeutics (SYRE) Long-Term Deferred Tax (2022) Analysis & Trends

Spyre Therapeutics has reported Long-Term Deferred Tax for 1 years, with the latest figure at $566000.0 in Q4 2022.

For the quarter ending Q4 2022, Long-Term Deferred Tax changed N/A year-over-year to $566000.0; the trailing twelve-month figure through Dec 2022 stood at $566000.0 (changed N/A YoY), and the FY2022 full-year result was $566000.0, changed N/A from the prior year.
Long-Term Deferred Tax for Q4 2022 stood at $566000.0.
The five-year high for Long-Term Deferred Tax was $566000.0 in Q4 2022, with the low at $566000.0 in Q4 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Spyre Therapeutics	6.95 Bn	6.95 Bn	-

Historic Data

Download Data

Date	Value
Dec 31, 2022	566,000.00